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Abstract
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide. Chronic liver disease due to viral hepatitis, 
alcohol, non-alcoholic fatty liver disease, etc are risk factors for HCC development. Triphasic contrast-enhanced computed tomography (CECT) 
and magnetic resonance imaging (MRI) abdomen are modalities for HCC diagnosis best for lesions >2 cm size. For lesions <2 cm size, liquid 
biopsy with the determination of cell-free DNA in the blood is a newly emerging technique for diagnosis as well as for the planning of molecular 
targeted therapy. With the new concept of “Treatment stage migration”, the updated Barcelona clinic liver cancer (BCLC) algorithm for HCC 
management allows the best treatment modality for an individual patient. In addition to definitive therapy of resection and liver transplantation, 
palliative therapies like ablation, transarterial embolization, and others can be used. Among molecular targeted therapies for advanced BCLC 
stage C HCC, lenvatinib as first line, regorafenib and cabozantinib as second line therapy have been approved recently. The checkpoint inhibitors 
(CPIs), nivolumab and pembrolizumab, have revolutionized oncology practice in other solid organ cancers and have shown promising results in 
HCC management.
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Background
Liver cancer has sixth ranking in new incident cancer cases 
all over the world and is the fourth leading cause of cancer- 
related deaths (1). The liver may have primary as well as 
metastatic involvement due to carcinoma. Overall, hepa-
tocellular carcinoma (HCC) is the most common primary 
liver cancer. The highest worldwide prevalence is in China 
and Mongolia, followed by intermediate prevalence in cen-
tral Europe and the lowest prevalence in North and South 
America, the Middle East, and Northern Europe. Variable 
prevalence exists in different parts of India. Asia contributes 
to about 75% of all liver cancer patients, out of these almost 
50% of cases originate in China, due to the high prevalence 
of chronic hepatitis B (CHB).
Chronic liver disease is an important risk factor for HCC 
development. CHB, chronic hepatitis C (CHC), and alcoholic 
liver disease used to be the leading causes of HCC. Among 
viral-related causes, hepatitis B virus (HBV) is responsible 
for 75–80% of cases and hepatitis C virus (HCV) for 10–20% 
of cases (2). Hepatitis delta virus infection increases the risk 
of HCC in CHB patients. Universal immunization for HBV 
and highly effective direct-acting antivirals (DAAs) in HCV 
are expected to decrease the proportion of patients with 
HCC due to viral causes.
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to understand the tumor biology. Based on these findings, a 
molecular classification of HCC has been proposed which has 
clinical and prognostic implications as well as it may guide in 
the selection of therapeutic modality. Two classes proliferative 
and non-proliferative have been suggested. The proliferative 
class has chromosomal instability with more prevalence of 
TP53 inactivation, cyclin D1 (CCND1), and fibroblast growth 
factor 19 (FGF19) amplifications leading to activation of 
RAS–MAPK (mitogen activated protein kinase), phosphati-
dylinositol-3-kinase (PI3K)/Akt and the mammalian target of 
rapamycin (mTOR) and tyrosine-protein kinase Met signaing 
pathways affecting cell proliferation and survival. Two sub-
classes S1 and S2 based on their pathways and gene activation 
have been proposed. HBV-related HCC belongs to the prolif-
erative class with poor outcomes (Figure 1).
The non-proliferative class has three subclasses with more 
heterogeneity. It is associated with HCV and alcoholic liver 
diseases. The canonical pathway of WNT-signaling and 
β-catenin mutation is characteristically involved in non- 
proliferative tumors.
As a part of “The Cancer Gene Atlas” (TCGA) research 
network, Wheelar et al. (15) performed a comprehensive 
integrated analysis of resected specimens of HCC among 
363 patients which included six data platforms DNA exome 
sequencing, DNA methylation, mRNA expressions, miRNA 
expressions, copy number data, and proteomics to understand 
the molecular landscape of HCC. The aim was to understand 
the clinical correlation with mutations and molecular markers, 
prognostication of various molecular classes, and for identifi-
cation of therapeutic targets based upon immunogenetics.
Chronic liver disease is associated with chronic inflamma-
tion with immune cell infiltration which over a long period 
increases the risk of HCC. Sia et al. (16) have suggested a 
novel immune-based classification of HCC. It comprises 
“Immune HCC” in ∼30% HCC with increased immune cell 
infiltration like cytotoxic T cells, macrophages, etc. associated 
with increased expression of programmed cell death receptor 
1 ligand 1 (PD-L1), PD-1, and IFN-γ signal and “Immune 
excluded” in ∼25% HCC with less chromosomal aberrations 
and decreased immune cell infiltration with CTNNB1 muta-
tion (16). Immune HCC class is further subdivided into “active 
immune” and “immune exhausted” classes. The immune HCC 
and immune excluded HCC classes overlap with prolifera-
tive and non-proliferative classes, respectively. However, 45% 
of HCC lie in the immune intermediate class at present due 
to their indeterminate genetic signatures. The immune-based 
classification may guide us for the development of immune 
checkpoint inhibitors (CPIs) for HCC in future.
Surveillance
Curative therapies like transplant and resection are rec-
ommended only for early-stage HCC with 5-year survival 
The emerging epidemic of metabolic syndrome and obesity 
has rapidly increased the prevalence of non-alcoholic fatty 
liver disease (NAFLD), which might become the leading 
cause of HCC in the near future as shown in liver transplant 
registry data from Western countries (3). The rising incidence 
of metabolic syndrome and NAFLD in Asian countries has 
also shown an increasing prevalence of HCC due to NAFLD. 
A study from Taiwan reported obesity having a four-fold 
increased risk of HCC in patients with CHC and two-fold 
risk of HCC in patients without viral infection. They also 
documented diabetes with two to three-fold increased risk of 
HCC development irrespective of viral infections (4). Almost 
5–30% HCCs have no identifiable cause and are classified 
as cryptogenic HCC. The presence of metabolic syndrome, 
diabetes, obesity, and dyslipidemia in past suggest for burnt-
out non-alcoholic steatohepatitis (NASH) (5, 6). Other risk 
factors for HCC are aflatoxin exposure, α1-antitrypsin defi-
ciency, tyrosinemia, hepatic porphyrias, etc.
Molecular Pathogenesis
Chronic liver disease (CLD) is associated with inflammation, 
fibrosis, and cirrhosis. The ongoing inflammation, injury, 
repair, and regeneration are responsible for the activation of 
genetic and epigenetic mechanisms of neoplasia resulting in 
the formation of dysplastic nodules which are precancerous 
lesions with high susceptibility to develop into HCC. HCC 
develops at a rate ∼3.5% per year and an average 10 years 
median time is needed for the development of HCC in cir-
rhosis (7). Various somatic genetic and epigenetic mutations 
telomerase reverse transcriptase (TERT), catenin beta-1 
(CTNNB1), axis inhibition protein 1 (AXIN1), tumor pro-
tein 53 (TP53), AT-rich interaction domain 1A (ARID1A), 
and ARID1B occur in CLD patients leading to activation of 
hepatocarcinogenic pathways like wingless-related integra-
tion site (WNT)–β-catenin signaling, receptor tyrosine kinase 
(RTK)–RAS–phosphatidylinositol 3-kinase (PI3K) cascades, 
oxidative stress, telomere shortening, and chromatin modifica-
tion (8–12). Unlike in other solid tumors, no single gene muta-
tion is responsible for HCC. This is why targeted molecular 
therapy for HCC has not been developed to date. HCC can 
also occur in the non-cirrhotic liver like in HBV infections, 
NASH, and uncommonly in benign lesions like hepatocellu-
lar adenomas (HCAs). TERT and CTNNB1 mutations have 
been documented to be associated with malignant transfor-
mation in <10% of HCAs (13). Almost 80% of HCC develop 
from mature hepatocytes; however, ∼20% may develop from 
hepatic progenitor cells or dedifferentiated hepatocytes (14).
Molecular Classifications
Researchers all over the world have done extensive genomic, 
epigenomic, and transcriptomic profiling of resected tumors 
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rates of  70% whereas only palliative treatment is possible 
for intermediate and advanced stage HCC with a median 
survival of  1–3 years. Chronic liver diseases pose a risk for 
HCC by chronic inflammation, fibrosis, and cirrhosis. CHB 
has a higher risk among males, African <40 years, with 
advanced fibrosis or cirrhosis (3–8% per year) and with a 
positive family history of  HCC. Cirrhosis due to HCV 
(3–5% per year), NASH, alcohol, primary biliary cholan-
gitis with stage 4 fibrosis, Wilson’s disease, hemochroma-
tosis, and α1-antitrypsin deficiency are other risk factors. 
Singal et al. (17) in a meta-analysis for HCC surveillance 
in patients with cirrhosis showed improvement in the detec-
tion rate of  early-stage HCC (Odds ratio [OR] 2.08, 95% 
confidence interval [CI] 1.80–2.37), higher treatment rate 
(OR 2.24, 95% CI 1.99–2.52), and better survival (OR 
1.90, 95% CI 1.67–2.17). HCC surveillance has uncertain 
benefits in HCV with stage 3 fibrosis, young HBV carri-
ers’ Asian males <40 years and females <50 years, and 
NAFLD without fibrosis. American Association for the 
study of  Liver Disease (AASLD) and European Associa-
tion for Study of  the Liver (EASL) guidelines jointly recom-
mend HCC surveillance with ultrasonography (USG) and 
alpha-fetoprotein  (AFP) levels 20 ng/mL at regular inter-
vals preferably every 6 months in cirrhosis of  the liver to 
be cost-effective. Computed tomography (CT) or magnetic 
resonance imaging (MRI) scan at present is not recom-
mended for HCC surveillance as they are not cost-effective 
and it is impractical to repeat them periodically except when 
ultrasound is inadequate (18). Park et al. (19) have shown 
limited non- enhanced MRI (Diffusion weighted imaging 
with T2; diffusion restriction with T2 hyperintensity) to be 
better than USG for HCC surveillance with higher sensi-
tivity (79% vs 28%), comparable specificity (98% vs 94%), 
higher positive predictive value (62% vs 17%), and compa-
rable negative predictive value (99% vs 97%). They showed 
limited MRI imaging having a study time duration of  6 
min with room occupancy time of  15–25 min as compared 
to 10–15 min for USG. On the other hand, Labgaa et al. 
(20) have recently demonstrated the presence of  cell-free 
DNA (cfDNA) in plasma samples of  patients with HCC for 
detecting somatic mutations in tumor tissues as a new min-
imally invasive method for determination of  HCC genet-
ics. The new technique called “Liquid biopsy” holds great 

























Figure 1: Molecular classification of HCC. Proliferation and non-proliferation class are characterized by mutations in different 
genes and associated with patients’ outcomes. 
T. Gupta
 Journal of Renal and Hepatic Disorders 2020;4(2): 51–60 54
Contrast-enhanced ultrasound is a better modality for 
HCC diagnosis in patients with contrast allergy or renal 
dysfunction. The liver imaging reporting and data system 
(LI-RADS) version 2018 has provided the algorithm for sur-
veillance, diagnosis, and assessment of treatment response 
for HCC to achieve a universal approach for standardization 
and consistency in image reporting (24). Features suggest-
ing HCC include enhancing capsule, non-rim arterial phase 
hyperenhancement, non-peripheral washout, size of tumor, 
and threshold growth of tumor over a duration on multi-
phase contrast-enhanced CT or MRI. On the USG size of 
the lesion, architectural distortion of the liver, venous throm-
bus in the liver, and refractive edge shadows around the 
lesion are features suggestive of HCC.
Staging
Hepatocellular carcinoma is a carcinoma that most fre-
quently arises in the background of cirrhosis. In any stag-
ing system in addition to tumor nodule numbers and size, 
the severity of liver dysfunction is taken into consideration. 
Decompensated cirrhosis has a large impact on the outcome 
of any therapy for HCC. The Barcelona clinic liver cancer 
(BCLC) staging system (25) is most accepted in various 
guidelines and practiced (Figure 3). The staging in BCLC is 
linked to most appropriate therapy for HCC according to the 
stage of tumor which includes nodule size and number along 
<2 cm in size, predicting the prognosis of  the lesion based 
upon certain genetic mutations and better selection of  ther-
apeutic modality based upon immunogenetics (21, 22).
Diagnosis
Hepatocellular carcinoma classically arises from dyspla-
sia of  cirrhotic nodules (Figure 2). During the dysplasia, 
the vascular supply dominantly becomes arterial and with 
malignant transformation, there is the formation of arte-
rioportal fistulas. The liver imaging by CT/MRI scan shows 
hyperenhancement of  HCC during the arterial phase due to 
rapid fill-in of  intravenous contrast and rapid washout of 
contrast during the portal venous phase when the rest of  the 
liver shows enhancement which becomes more pronounced 
during delayed venous phases. A recent meta-analysis by 
Roberts et al. (23) has demonstrated higher sensitivity (0.82 
vs 0.66), comparable specificity (0.91 vs 0.92) with lower 
negative likelihood ratio (0.20 vs 0.37), and comparable 
positive likelihood ratio (8.8 vs 8.1) for triphasic contrast 
MRI and CT scan, respectively. However, MRI for <1 cm 
size nodule had higher sensitivity (0.69 vs 0.49) and lower 
specificity (0.46 vs 0.69) than a CT scan. On the other hand, 
MRI should not be the first choice for patients with asci-
tes (artefacts), poor breath-hold (artefacts), and decompen-
sated liver disease (poor gadoxetate sodium uptake by liver 
parenchyma).






















Figure 2: Algorithm for diagnosis of single liver nodule.
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Clinical Management
Surgical Modalities
Among all the treatment modalities available, surgical 
options like hepatic resection and liver transplantation are 
the best. Hepatic resection has evolved dramatically over 
time due to a laparoscopic/minimally invasive approach. In 
BCLC staging, there was a mono-parametric approach to 
the selection of patients with single tumors, Child A cirrho-
sis, early portal hypertension with hepatic vein portal system 
gradient (HVPG) ≤10 mmHg or bilirubin ≤17  µMol/L for 
hepatic resection. However, a multi-parametric approach 
based upon Child A cirrhosis with model for end stage liver 
disease (MELD)<10 with an acceptable grade of portal 
hypertension, acceptable remaining liver parenchyma after 
resection to achieve adequate hepatic function, and adopt-
ing a laparoscopic/minimally invasive approach for surgical 
treatment of HCC has come into practice (32). This allows 
to include patients who were previously denied liver resec-
tion. Post hepatic liver failure (PHLF) is the most import-
ant complication of hepatic resection. Prodeau et al.  (33) 
have recently proposed an ordinal model based upon 
with intrahepatic or extrahepatic vascular invasion, extrahe-
patic metastases, Child–Pugh class for the severity of liver 
decompensation, and performance status of the patient as 
assessed by Eastern Cooperative Oncology Group (ECOG) 
criteria. This is imperative to understand that selection of 
therapy and its best outcome is always dependent on the 
extent of liver disease in a given patient. There are other stag-
ing systems like the Cancer of the Liver Italian Program (26) 
and the Hong Kong Liver Cancer staging  system (27); how-
ever, they are more geographically restricted. Over the years, 
experts have found that the BCLC staging system has a rigid 
approach with a selection of patients best for stage associated 
therapy rather than the best treatment modality for a given 
patient. Various studies have also shown superior results for 
aggressive surgical approach than locoregional therapy in 
HCC. Therefore, the concept of “treatment stage migration” 
is emerging with either “left to right” or even “right to left” 
shift for selection of therapy in the BCLC algorithm (28). 
This means considering liver resection in patients with either 
vascular invasion or consideration of liver transplantation in 
patients with downstaging of tumor with locoregional ther-
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Figure 3: The Barcelona Clinic Liver Cancer (BCLC) staging system. PS: performance status.
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pre-operative variables such as liver remnant volume ratio, 
platelet count, and intent-to-treat laparoscopy with intraop-
erative variables like intra-operative blood loss and per pro-
tocol, laparoscopy to predict symptomatic PHLF in cirrhosis 
with HCC patients. Overall resection provides 60% survival 
with an HCC recurrence rate of ∼70% at 5 years (34).
Liver transplantation (LT) is the next surgical option for 
patients with HCC in whom liver resection is not feasible. LT 
not only removes the tumor but also cures liver disease. The 
BCLC algorithm allocates orthotopic LT (OLT) for HCC 
fulfilling Milan’s criteria (35) (single tumor ≤5 cm and ≤3 
nodules ≤3 cm size). OLT has a survival rate of 60–80% at 
5th year and 50% at 10th year with tumor recurrence rate 
of 15%. The University of California San Francisco (UCSF) 
criteria are more relaxed including larger tumor size albeit 
with low survival rates. Mazaferro et al. (36) introduced the 
concept of Metroticket 2.0 model where tumor size and AFP 
levels were used to make a model with an expected 5-year sur-
vival of 70% after OLT. The model depicted that with AFP 
<200 ng/mL, the sum of tumor number and size (cm) should 
be ≤7; with AFP 200–400 ng/mL tumor size and number 
sum should be ≤5; with AFP 400–1000 ng/mL tumor num-
ber and size sum should be ≤4. Today in the Era of neoadju-
vant therapies for downstaging of HCC, Cucchetti et al. (37) 
have recently demonstrated better prediction of post-liver 
transplant HCC related 5-year mortality after the addition 
of mRECIST criteria to Metroticket 2.0 model especially 
in patients with partial/stable response and progressive dis-
ease as assessed by mRECIST criteria. The hepatic resection 
leaves the cirrhotic liver behind which may have unidentified 
dysplastic nodules at the time of resection or naïve nodules 
developing later on resulting in a high tumor recurrence rate 
than LT. However, LT is not the first surgical modality due 
to donor organ availability issues and transplant waitlist 
mortality.
Tumor Ablation
BCLC stage 0 or A HCC, which are ineligible for surgical 
options are taken up for ablative therapies. Various ablative 
modalities like radiofrequency ablation (RFA), microwave, 
and cryotherapy are available. RFA unipolar or multipolar 
is most commonly practiced. It ablates the tumor with heat 
effect which is applied through an electrode placed inside 
the tumor under USG guidance. Zhang et al. (38) showed 5- 
and 10-year survival of 66 and 35% with RFA, respectively. 
A recent meta-analysis for RFA in HCC revealed that albu-
min-bilirubin score 0, Child A cirrhosis, single tumor nodule 
<2 cm, and AFP <20 ng/mL were predictive of overall sur-
vival (OS) and recurrence-free survival (RFS) (39). Another 
meta-analysis analyzed studies comparing surgical resection 
with RFA and found resection to be superior for overall 
and disease-free survival (DFS) in patients with resectable 
HCC (40).
Trans Arterial Therapies
The conventional trans arterial chemoembolization (TACE) 
is a therapeutic modality for intermediate-stage HCC (stage 
B) without any vascular invasion or extrahepatic spread in 
which cytotoxic agent mixed with lipiodol is infused intraar-
terially into the tumor followed by vessel embolization by 
gel foam or microspheres. The drug-eluting beads TACE 
(DEB-TACE) uses non-absorbable embolic microspheres 
loaded with anthracyclines which stay in the tumor. Stud-
ies have shown non-superiority of DEB-TACE in terms of 
1- and 2-year survival rates, tumor response rates, and a 
median time to progression of tumor to conventional TACE 
(cTACE) (41). A recent meta-analysis has shown no statisti-
cally significant difference in adverse events between the two 
groups (42). The recently updated algorithm has included 
the use of TACE as bridging therapy to liver transplant, for 
HCC with segmental portal vein thrombosis, use of TACE 
in combination with sequential therapy with ablation for 
lesions up to 7 cm or for recurrent intrahepatic lesions up to 
3 cm (43).
Selective internal radiation therapy (SIRT) is the next 
trans arterial mode of therapy using microspheres loaded 
with radioisotope yttrium-90 without embolization for 
anti-tumoral activity. The SorAfenib versus Radioemboliza-
tion in Advanced Hepatocellular carcinoma (SARAH) trial 
from France and Selective Internal Radiation Therapy vs. 
Sorafenib (SIRveNIB) trial from the Asia-pacific region in 
advanced HCC found no significant difference in OS between 
SIRT and sorafenib for BCLC stage C patients (44, 45).
Molecular Targeted Therapies
Sorafenib, a multikinase inhibitor, was first approved in 
2008 for advanced unresectable HCC BCLC stage C where 
other curative therapies are futile (46, 47). It inhibits several 
tyrosine kinases like platelet-derived growth factor recep-
tor (PDGF-R), vascular endothelial growth factor receptor 
(VEGFR), Flt3, c-Kit, and Raf kinases of MAPK/ERK 
pathway. It provided a survival benefit of 10.7 months as 
compared to 7.9 months with placebo (46, 47). Subsequently, 
many drugs were investigated like brivanib, erlotinib, tivan-
tinib, linifanib, sunitinib, and everolimus which did not show 
a survival benefit in comparison with placebo (48–52). In 
2018, the FDA approved lenvatinib based upon a non-infe-
riority trial with a median survival of 13.6 months as com-
pared to 12.3 months with sorafenib (53). Both sorafenib 
and lenvatinib are first-line therapy for HCC.
Regorafenib is another multikinase inhibitor target-
ing PDGFR, VEGFR, KIT, RET, FGFR1, and TIE-2 
and has got FDA approval in 2017 as second-line therapy 
for advanced HCC (54). Cabozantinib based upon Celes-
tial trial (55) got approval as second- or third-line therapy 
for HCC in 2019. Ramucirumab, a monoclonal antibody 
against VEGFR2 has shown an extended OS of 8.5 months 
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the emerging epidemic of NASH and metabolic syndrome. 
Emerging research on the molecular landscape of HCC shall 
improve surveillance and diagnostic modalities. The con-
cept of “Treatment stage migration” with “right to left” or 
“left to right” shift in the BCLC algorithm has improved the 
selection of treatment modality for an individual patient. 
The immune classification of HCC may open ways to bet-
ter understanding for use of CPIs. Further translational 
research is needed to correctly identify patients who will do 
best on multikinase inhibitors, VEGFR inhibitors, or immu-
notherapy. Finally, a lot more research is needed to identify 
the effective combination of different modalities of HCC 
treatment to achieve the best results.
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